Dr Nathan Peiffer Smadja12 Nov 2020 21:46
Dr Nathan Peiffer-Smadja, an expert in Internal Medicine and Infectious Diseases at Imperial College London Said
'The number of patients enrolled in this pilot clinical trial is of course small.
(Which we all knew but now in 22 countries)
'In addition, this study neither showed ANY impact of the evaluated treatment on time to discharge nor on mortality, although the study was obviously not powered to respond to the latter question.
(This is obviously not good but when 3 patients on placebo died and none on SNG001 died how can this be said)
“nebulisation of interferon has no marketing authorisation for any indication yet'
(Yet we are awaiting FDA, EUA, MHRA)
Has the mail got this quote from the Doctor or is it in the Lancet review?